If you are living with HIV, one issue that may be challenging is lipodystrophy. Lipodystrophy refers to changes in body fat that include buildup or loss of fat in certain areas of the body. Hard Belly (excess hard abdominal fat) results when the buildup of extra hard fat in the abdominal (belly) area pushes up against the abdominal wall and stretches the muscles until they become taut.
Hard Belly fat is not like regular fat. Regular fat sits just under the skin (subcutaneous fat) and is soft and squishy or easy to pinch or move around.
*EGRIFTA SV™ is not approved to reduce the health consequences of Hard Belly (excess hard abdominal fat).
A number of factors may increase the risk of developing Hard Belly (excess hard abdominal fat), including:
Feeling your abdomen (belly) for firmness
Measuring your waist and hips
Calculating waist-to-hip ratio (waist circumference/hip circumference)
If you have trouble managing Hard Belly (excess hard abdominal fat) on your own with exercise and a healthy diet, ask your healthcare provider about EGRIFTA SV™, which has been shown to reduce Hard Belly (excess hard abdominal fat) in people living with HIV who have lipodystrophy.
†A newly approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.